Vitamin D Supplementation in Adolescents and Young Adults With Juvenile Systemic Lupus Erythematosus for Improvement in Disease Activity and Fatigue Scores: A Randomized, Double-Blind, Placebo-Controlled Trial

Imagem de Miniatura
Arquivos
art_DEGASPARE_When_Is_the_Appropriate_Time_for_Pediatric_Acute_2015.PDF (125.82 KB)
Citações na Scopus
109
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
Citação
ARTHRITIS CARE & RESEARCH, v.68, n.1, p.91-98, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective. Vitamin D has an important immunomodulatory effect, but there are no trials that directly address the boosting of serum levels of 25-hydroxyvitamin D (25[ OH] D) in juvenile-onset systemic lupus erythematosus (SLE). The aim of this study was to evaluate the effect of vitamin D supplementation on disease activity and fatigue in juvenile-onset SLE. Methods. This study was a randomized, double-blind, placebo-controlled, 24-week trial. Forty juvenile-onset SLE patients were randomized (1: 1) to receive oral cholecalciferol 50,000 IU/week (juvenile-onset SLE-VitD) or placebo (juvenile-onset SLE-PL). Medications remained stable throughout the study. Serum levels of 25(OH) D were measured using radioimmunoassay. Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the European Consensus Lupus Activity Measurement (ECLAM). Fatigue was assessed using the Kids Fatigue Severity Scale (K-FSS). Results. At baseline, groups were similar regarding age, body mass index, organ involvement, glucocorticoid dose, use of immunosuppressive drugs, SLEDAI, ECLAM, K-FSS, and levels of 25(OH) D. After 24 weeks, the mean level of 25(OH) D was higher in the juvenile-onset SLE-VitD group than in the juvenile-onset SLE-PL group (P < 0.001). At the end of the intervention, a significant improvement in SLEDAI (P = 0.010) and in ECLAM (P = 0.006) was observed in the juvenile-onset SLE-VitD group compared to the juvenile-onset SLE-PL group. Regarding fatigue evaluation, a reduction of fatigue related to social life score was found in the juvenile-onset SLE-VitD group compared to the juvenile-onset SLE-PL group (P = 0.008). Cholecalciferol was well tolerated with no serious adverse events. Conclusion. This study suggests that cholecalciferol supplementation for 24 weeks is effective in decreasing disease activity and improving fatigue in juvenile-onset SLE patients.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/13387
Referências
  1. Amital H, 2010, ANN RHEUM DIS, V69, P155
  2. WYSENBEEK AJ, 1993, BRIT J RHEUMATOL, V32, P633
  3. Hypponen E, 2010, DIABETES OBES METAB, V12, P737, DOI 10.1111/j.1463-1326.2010.01211.x
  4. de Borst MH, 2011, CURR DRUG TARGETS, V12, P97
  5. KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121
  6. Schmeding A, 2013, BEST PRACT RES CL RH, V27, P363, DOI 10.1016/j.berh.2013.07.009
  7. Ruiz-Irastorza G, 2010, ARTHRIT CARE RES, V62, P1160, DOI 10.1002/acr.20186
  8. Wright TB, 2009, J PEDIATR-US, V155, P260, DOI 10.1016/j.jpeds.2009.02.033
  9. Yang CY, 2013, CLIN REV ALLERG IMMU, V45, P217, DOI 10.1007/s12016-013-8361-3
  10. Abou-Raya A, 2013, J RHEUMATOL, V40, P265, DOI 10.3899/jrheum.111594
  11. Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928
  12. Sahebari M, 2014, LUPUS, V23, P1164, DOI 10.1177/0961203314540966
  13. Birmingham DJ, 2012, LUPUS, V21, P855, DOI 10.1177/0961203312439640
  14. Casella CB, 2012, LUPUS, V21, P1335, DOI 10.1177/0961203312454929
  15. Fuchs SC, 2002, BMC PUBLIC HEALTH, V2, DOI 10.1186/1471-2458-2-1
  16. BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606
  17. Kiani AN, 2013, RHEUMATOLOGY, V52, P2071, DOI 10.1093/rheumatology/ket271
  18. Cutolo M, 2009, ANN RHEUM DIS, V68, P446, DOI 10.1136/ard.2008.093476
  19. Stockton KA, 2012, LUPUS, V21, P271, DOI 10.1177/0961203311425530
  20. Peracchi OAB, 2014, BRAZ J MED BIOL RES, V47, P721, DOI 10.1590/1414-431X20143948
  21. Antico A, 2012, AUTOIMMUN REV, V12, P127, DOI 10.1016/j.autrev.2012.07.007
  22. Cutolo M, 2008, LUPUS, V17, P6, DOI 10.1177/0961203307085879
  23. Munger KL, 2006, JAMA-J AM MED ASSOC, V296, P2832, DOI 10.1001/jama.296.23.2832
  24. Gatenby P, 2013, CURR OPIN RHEUMATOL, V25, P184, DOI 10.1097/BOR.0b013e32835cfc16
  25. Bonakdar ZS, 2011, LUPUS, V20, P1155, DOI 10.1177/0961203311405703
  26. Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198-007-0394-0
  27. Ruiz-Irastorza G, 2008, RHEUMATOLOGY, V47, P920, DOI 10.1093/rheumatology/ken121
  28. Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385
  29. Ritterhouse LL, 2011, ANN RHEUM DIS, V70, P1569, DOI 10.1136/ard.2010.148494
  30. Tench CM, 2000, RHEUMATOLOGY, V39, P1249, DOI 10.1093/rheumatology/39.11.1249
  31. Kamen D, 2008, CURR OPIN RHEUMATOL, V20, P532, DOI 10.1097/BOR.0b013e32830a991b
  32. Arnson Y, 2007, ANN RHEUM DIS, V66, P1137, DOI 10.1136/ard.2007.069831
  33. BENCIVELLI W, 1992, CLIN EXP RHEUMATOL, V10, P549
  34. Schneider L, 2014, CLIN RHEUMATOL, V33, P1033, DOI 10.1007/s10067-014-2530-5
  35. Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
  36. Kamen DL, 2006, AUTOIMMUN REV, V5, P114, DOI 10.1016/j.autrev.2005.05.009
  37. Cutolo M, 2009, RHEUMATOLOGY, V48, P210, DOI 10.1093/rheumatology/ken394
  38. Stagi S, 2014, LUPUS, V23, P1059, DOI 10.1177/0961203314532564
  39. Zold E, 2011, VITAM HORM, V86, P261, DOI 10.1016/B978-0-12-386960-9.00011-3
  40. Wortsman J, 2000, AM J CLIN NUTR, V72, P690
  41. Chaiamnuay S, 2013, JCR-J CLIN RHEUMATOL, V19, P121, DOI 10.1097/RHU.0b013e318289bd16
  42. DeLuca Hector F, 2004, Am J Clin Nutr, V80, p1689S
  43. Hamza RT, 2011, MED SCI MONITOR, V17, P711
  44. Houghton KM, 2008, ARTHRIT RHEUM-ARTHR, V59, P537, DOI 10.1002/art.23534
  45. Mandal M, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4479
  46. Petri M, 2013, ARTHRITIS RHEUM-US, V65, P1865, DOI 10.1002/art.37953
  47. Robinson AB, 2014, LUPUS SCI MED, V1, DOI 10.1136/LUPUS-2014-000011
  48. Terrier B, 2012, ARTHRITIS RES THER, V5, pR221

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/17
Artigos e Materiais de Revistas Científicas - LIM/36